TerminatedNot Applicable

Ticagrelor CytoSorb Hemoadsorption

Stopped: Stalled study execution from the impact of the COVID-19 pandemic on the UK NHS

United Kingdom5 participantsStarted 2019-10-29

Plain-language summary

TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart. The hypothesis of TISORB is that removal of ticagrelor by the CytoSorb device during surgery will decrease the risk for surgical bleeding from ticagrelor.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Cardiothoracic surgery requiring cardiopulmonary bypass ≤ 48 hours following the last dose of ticagrelor. Exclusion Criteria: Any cardiothoracic surgery \> 48 hours after last dose of ticagrelor.

What they're measuring

Primary Pharmacodynamic Endpoint

Timeframe: Immediately before and after cardiopulmonary bypass

Primary Pharmacokinetic Endpoint

Timeframe: Immediately before and after cardiopulmonary bypass

Trial details

NCT IDNCT04131959

SponsorCytoSorbents, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-05-04

Results submitted2022-01-18

View on ClinicalTrials.gov More Emergent Cardiothoracic Surgery trials